| Income statement (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106.10B | 100.43B | 105.69B | 102.87B | 98.92B | 94.59B | 97.71B | 95.43B |
| Cost of revenue | 58.86B | 55.44B | 59.06B | 57.05B | 54.01B | 51.06B | 55.27B | 52.95B |
| Gross profit | 47.23B | 44.98B | 46.63B | 45.83B | 44.91B | 43.53B | 42.44B | 42.48B |
| Operating expenses | 101.39B | 95.75B | 103.58B | 106.08B | 96.53B | 91.21B | 95.34B | 94.60B |
| Operating income | 4.70B | 4.68B | 2.11B | -3.21B | 2.38B | 3.37B | 2.37B | 832.00M |
| EBITDA | 5.83B | 5.79B | 3.26B | -2.07B | 3.55B | 4.53B | 3.52B | 1.99B |
| Interest expense | 757.00M | 774.00M | 787.00M | 784.00M | 763.00M | 785.00M | 758.00M | 752.00M |
| Income before tax | 3.98B | 3.94B | 1.35B | -3.48B | 1.65B | 2.62B | 2.13B | 105.00M |
| Income tax | 982.00M | 981.00M | -1.57B | 508.00M | 634.00M | 835.00M | 503.00M | 34.00M |
| Net income | 2.98B | 2.94B | 2.94B | -3.98B | 1.02B | 1.78B | 1.64B | 87.00M |
| EPS | 2.33 | 2.31 | 2.33 | -3.13 | 0.81 | 1.41 | 1.31 | 0.07 |
| EPS (diluted) | 2.31 | 2.30 | 2.32 | -3.13 | 0.80 | 1.41 | 1.31 | 0.07 |
| Diluted shares | 1.29B | 1.28B | 5.00M | 1.27B | 1.27B | 1.26B | 0 | 1.26B |
| Dividends per share | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 |
From CVS Health's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.